Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Spoor Johan M. reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. reported that Chief Executive Officer Johan M. Spoor was granted stock options covering 735,000 shares on the March 2, 2026 grant date. The award, approved by the board on January 26, 2026, represents his annual 2026 equity grant. The options vest in 48 substantially equal monthly installments starting one month after the grant date, contingent on his continued service.
Perspective Therapeutics reported that Chief Accounting Officer Jonathan Robert Hunt received a grant of stock options representing the right to buy 90,000 shares, with a grant date of March 2, 2026. These options were approved by the board’s compensation committee as his annual equity award for 2026.
The options have a stated exercise price of $0.0000 per share and vest over four years in 48 substantially equal monthly installments starting one month after the grant date, conditioned on his continued service with the company.
Perspective Therapeutics, Inc. reported that Chief Medical Officer Markus Puhlmann received a grant of stock options covering 150,000 shares on the grant date of March 2, 2026. The options were approved by the compensation committee as his annual equity award for 2026 and have an exercise price of $0.0000 per share.
The option award vests and becomes exercisable over four years in 48 substantially equal monthly installments, starting one month after the grant date, so long as he continues serving the company on each vesting date. This is a routine equity compensation grant rather than an open‑market share purchase or sale.
Morgan Stanley has filed a Schedule 13G reporting a significant ownership stake in Perspective Therapeutics, Inc. common stock. As of 12/31/2025, Morgan Stanley reports beneficial ownership of 4,461,893 shares, representing 6.0% of the company’s common stock.
The firm reports no sole voting or dispositive power, with shared voting power over 3,386,203 shares and shared dispositive power over 3,555,365 shares. Morgan Stanley certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Perspective Therapeutics.
Perspective Therapeutics, Inc. received a Schedule 13G from Commodore Capital entities and principals reporting passive ownership of 11,939,753 shares of common stock. This represents 9.9 % of the company’s common shares as of early February 2026.
The position includes 6,336,782 common shares plus 5,602,971 shares issuable upon exercise of a pre-funded warrant that is capped by a 9.99 % beneficial ownership limitation. An additional 995,075 warrant shares are excluded because of this cap. The filers certify the stake is not held to change or influence control of the company.
Perspective Therapeutics, Inc. (CATX) received a Schedule 13G reporting a significant but non-controlling ownership position by TCG Crossover funds and Chen Yu. The filing shows that Chen Yu may be deemed to beneficially own 7,915,567 shares of common stock, equal to 6.9% of the company’s 113,914,078 shares of common stock outstanding.
The holdings are split between TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., which each report beneficial ownership of 3,957,784 and 3,957,783 shares, respectively, or 3.5% of the class each. The reporting parties certify the shares were not acquired to change or influence control of Perspective Therapeutics.
Qatar Investment Authority disclosed a significant passive stake in Perspective Therapeutics Inc. common stock. As of 02/04/2026, it beneficially owned 7,073,308 shares, representing 6.2% of the class, with sole voting and sole dispositive power over all reported shares.
The filing notes that Q Healthcare Holding LLC, a wholly owned subsidiary of Qatar Investment Authority, acquired the securities. Qatar Investment Authority certifies the shares were not acquired to change or influence control of Perspective Therapeutics, indicating a passive investment position.
Perspective Therapeutics, Inc. completed an underwritten equity offering, selling 39,576,088 shares of common stock and issuing pre-funded warrants to purchase 6,598,046 shares, raising approximately $175 million in gross proceeds.
The shares were priced at $3.79 each, and the pre-funded warrants at $3.789 each, reflecting a $0.001 exercise price. The company plans to use net proceeds to advance clinical development of its product candidates, invest in manufacturing facilities, and for working capital and other general corporate purposes, with potential additional use for future acquisitions or licensing opportunities.
Perspective Therapeutics, Inc. is conducting a primary offering of 39,576,088 shares of common stock and pre-funded warrants to purchase 6,598,046 shares of common stock. The shares are priced at $3.79 and the pre-funded warrants at $3.789, with a $0.001 exercise price per warrant share.
The company expects gross proceeds of $174,993,369.81 and net proceeds of approximately $164.0 million after underwriting discounts and expenses. Management plans to use the cash to advance clinical development of its radiopharmaceutical product candidates, invest in manufacturing facilities, and for working capital and general corporate purposes, with potential business development uses.
As of December 31, 2025, Perspective Therapeutics estimates it had approximately $144 million in cash, cash equivalents and short-term investments, and about 74.3 million shares outstanding. The company believes existing cash plus this raise should fund planned milestones and operations into late 2027, though investors will face immediate dilution given the offering price exceeds prior net tangible book value per share.
Perspective Therapeutics, Inc. filed an 8-K to note that it has updated its corporate presentation and posted it on its website. The presentation includes preliminary estimated and projected financial information, including estimated cash, cash equivalents and short-term investments as of December 31, 2025.
The company emphasizes that these figures are unaudited and have not been reviewed or compiled by its independent registered public accounting firm, WithumSmith+Brown, PC, which provides no assurance on the data. Actual results for the year ended December 31, 2025 may differ once closing procedures and final adjustments are completed.